We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Peroxidase Mimic Outperforms Natural Horseradish Peroxidase in ELISA Test

By LabMedica International staff writers
Posted on 29 Sep 2015
A test-of-concept study demonstrated that a synthetic catalyst that mimics the action of horseradish peroxidase (HRP) could increase the sensitivity of a colorimetric enzyme-linked immunosorbent assay (ELISA) for human prostate surface antigen (PSA) by more than 110-fold.

Peroxidase mimics with dimensions on the nanoscale have received great interest as emerging artificial enzymes for biomedicine and environmental protection. More...
While a variety of peroxidase mimics have been developed recently, limited progress has been made toward improving their catalytic efficiency.

In a study published in the September 3, 2015, online edition of the journal ACS Nano, investigators at Michigan Technological University (Houghton, USA) and colleagues at Louisiana State University (Baton Rouge, USA) and the University of Texas at Dallas (USA) described a novel peroxidase mimic made by depositing Ir (iridium) atoms as ultrathin skins (a few atomic layers) on Pd (palladium) nanocubes.

These Pd–Ir nanocubes exhibited significantly enhanced efficiency, with catalytic constants more than 20- and 400-fold higher than those of an older version of Pd cubes and horseradish peroxidase (HRP), respectively.

In a proof-of-concept demonstration, the Pd–Ir nanocubes were used in a colorimetric ELISA for human prostate surface antigen (PSA). The modified assay was found to have a detection limit of 0.67 picograms per milliliter, which was about 110-fold lower than that of the conventional HRP-based ELISA using the same set of antibodies and the same procedure.

The Pd–Ir nanocubes were prepared by chemists at the Michigan Technological University. Investigators at Louisiana State University conducted theoretical calculations, and colleagues at the University of Texas at Dallas obtained high-resolution electron microscopy images.

"After surgery, it is vital to detect a tiny amount of prostate antigen, because otherwise you can get a false negative and perhaps delay treatment for cancer," said senior author Dr. Xiaohu Xia, assistant professor of chemistry at Michigan Technological University. "We wanted to develop a mimic peroxidase that was substantially more efficient than the natural peroxidase, which would lead to a more-sensitive PSA test. Our ultimate goal is to further refine our system for use in clinical diagnostic laboratories."

Related Links:

Michigan Technological University
Louisiana State University
University of Texas at Dallas



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.